CD122-selective IL-2 complexes target γδ T and NK cells to reduce tumor-promoting Th17 effects and synergize with αPD-L1 to treat primary and metastatic bladder cancer

Authors :: Ryan Michael Reyes
Yilun Deng
Deyi Zhang
Neelam Mukherjee
Niannian Ji
Karen Wheeler
Harshita B. Gupta
Myrna Garcia
Anand Kornepati
Robert S Svatek
Tyler J Curiel
Source :: The Journal of Immunology. 204:88.14-88.14
Publication Year :: 2020
Publisher :: The American Association of Immunologists, 2020.
Abstract: αPD-L1 bladder cancer (BC) immunotherapy is effective in

Full Text Access

Tools